Package Leaflet: Information for the User
Sitagliptin/Metformin Almus 50 mg/1,000 mg film-coated tablets EFG
sitagliptin/metformin hydrochloride
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Sitagliptin/metformin contains two different medicines called sitagliptin and metformin.
They work together to control blood sugar levels in adult patients with a form of diabetes called “type 2 diabetes mellitus”. This medicine helps increase the amount of insulin produced after a meal and reduces the amount of sugar produced by your body.
Together with diet and exercise, this medicine helps lower your blood sugar levels. This medicine can be used alone or with certain diabetes medicines (insulin, sulfonylureas, or glitazones).
What is type 2 diabetes? Type 2 diabetes is a disease in which your body does not produce enough insulin and the insulin your body produces does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart diseases (cardiac), kidney diseases (renal), blindness, and amputations.
Do not take Sitagliptin/Metformin Almus
if you have severe kidney problems
Do not take sitagliptin/metformin if any of the above applies to you and consult your doctor about other ways to control your diabetes. If you are not sure, consult your doctor, pharmacist, or nurse before taking this medicine.
Warnings and precautions
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin/metformin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking this medicine.
Risk of lactic acidosis
Sitagliptin/metformin may cause a very rare but very serious side effect called lactic acidosis, especially if your kidneys are not working properly. The risk of developing lactic acidosis is also increased with uncontrolled diabetes, severe infections, prolonged fasting, or alcohol intake, dehydration (see more information below), liver problems, and any medical condition in which a part of your body has a reduced supply of oxygen (such as severe and acute heart diseases).
If any of the above applies to you, consult your doctor for further instructions.
Stop taking sitagliptin/metformin for a short period if you have a condition that may be associated with dehydration(significant loss of body fluids), such as severe vomiting, diarrhea, fever, exposure to heat, or if you drink less fluid than usual. Consult your doctor for further instructions.
Stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately if you experience any of the symptoms of lactic acidosis, as this condition can lead to coma.
The symptoms of lactic acidosis include:
Lactic acidosis is a medical emergency and must be treated in a hospital.
Consult your doctor or pharmacist before starting to take this medicine:
If you need to undergo major surgery, you should stop taking sitagliptin/metformin during the procedure and for a period after. Your doctor will decide when you should stop and restart taking sitagliptin/metformin.
If you are not sure if any of the above applies to you, consult your doctor or pharmacist before taking this medicine.
During treatment with sitagliptin/metformin, your doctor will check your kidney function at least once a year or more frequently if you are an elderly person and/or if your kidney function is worsening.
Consult your doctor promptly if:
Children and adolescents
Children and adolescents under 18 years should not use this medicine. It is not effective in children and adolescents aged 10 to 17 years. It is not known if this medicine is safe and effective when used in children under 10 years.
Other medicines and Sitagliptin/Metformin Almus
If you need to be given an injection of a contrast agent containing iodine into your bloodstream, for example, in the context of an X-ray or scan, you should stop taking this medicine before or at the time of the injection. Your doctor will decide when you should stop and restart taking sitagliptin/metformin.
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines. You may need more frequent blood glucose and kidney function tests, or your doctor may need to adjust the dose of this medicine. It is especially important to mention the following:
diseases that cause inflammation, such as asthma and arthritis (corticosteroids)
Taking Sitagliptin/Metformin Almus with alcohol
Avoid excessive alcohol intake while taking this medicine, as this may increase the risk of lactic acidosis (see section “Warnings and precautions”).
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. You should not take this medicine during pregnancy or while breast-feeding. See section 2, Do not take Sitagliptin/Metformin Almus.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible or non-existent. However, there have been reports of dizziness and drowsiness during treatment with sitagliptin, which may affect your ability to drive or use machines.
Taking this medicine with sulfonylureas or insulin may cause low blood sugar levels (hypoglycemia), which may affect your ability to drive or use machines or work without a secure support.
Sitagliptin/Metformin Almus contains sodium
This medicine contains less than 23 mg of sodium (1 mmol) per tablet; this is essentially “sodium-free”.
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
You should continue with the diet recommended by your doctor during treatment with this medicine and be careful to distribute your carbohydrate intake evenly throughout the day.
It is unlikely that treatment with this medicine alone will cause abnormally low blood sugar levels (hypoglycemia). Low blood sugar levels can occur when this medicine is taken with a sulfonylurea or insulin, so your doctor may need to reduce the dose of your sulfonylurea or insulin.
The score line is not intended to break the tablet.
If you take more Sitagliptin/Metformin Almus than you should
If you take more than the prescribed dose of this medicine, contact your doctor immediately. Go to the hospital if you have symptoms of lactic acidosis such as feeling cold or unwell, nausea or vomiting, stomach pain, weight loss, muscle cramps, or rapid breathing (see section “Warnings and precautions”).
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to take Sitagliptin/Metformin Almus
If you miss a dose, take it as soon as you remember. If you do not remember until the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take a double dose of this medicine.
If you stop taking Sitagliptin/Metformin Almus
Keep taking this medicine for as long as your doctor recommends. It will help control your blood sugar levels. Do not stop taking this medicine without first talking to your doctor. If you stop taking sitagliptin/metformin, your blood sugar levels may increase again.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
STOP taking sitagliptin/metformin and go to the doctor immediately if you notice any of the following serious adverse effects:
back with or without nausea and vomiting, as these can be signs of pancreatitis (inflammation of the pancreas).
This medicine may cause a very rare (may affect up to 1 in 10,000 people) but very serious adverse effect called lactic acidosis (see section "Warnings and Precautions"). If this happens to you, you must stop taking sitagliptin/metformin and contact a doctor or the nearest hospital immediately, as lactic acidosis can lead to coma.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/desquamation of the skin and swelling of the face, lips, tongue, and throat that can cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change the medicine for the treatment of diabetes.
Some patients who took metformin have experienced the following adverse effects after starting treatment with sitagliptin:
Frequent (may affect up to 1 in 10 people): low blood sugar, nausea, gas, vomiting
Infrequent (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, drowsiness
Some patients have experienced diarrhea, nausea, gas, constipation, stomach pain, or vomiting when starting treatment with the combination of sitagliptin and metformin (frequency classified as frequent).
Some patients have experienced the following adverse effects when taking this medicine along with a sulfonylurea such as glimepiride:
Very frequent (may affect more than 1 in 10 people): low blood sugar levels
Frequent: constipation
Some patients presented the following adverse effects while taking this medicine in combination with pioglitazone:
Frequent: swelling of hands or feet
Some patients presented the following adverse effects while taking this medicine in combination with insulin:
Very frequent: low blood sugar levels
Infrequent: dry mouth, headache
Some patients have experienced the following adverse effects during clinical trials while taking sitagliptin alone (one of the medicines that contains this medicine) or during use after the approval of sitagliptin/metformin or sitagliptin alone or with other diabetes medicines:
Frequent: low blood sugar, headache, upper respiratory tract infection, nasal congestion or nasal discharge and sore throat, arthrosis, pain in the arm or leg
Infrequent: dizziness, constipation, itching
Rare: reduction in platelet count
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of skin blister)
Some patients have experienced the following adverse effects after taking metformin alone:
Very frequent: nausea, vomiting, diarrhea, stomach pain, and loss of appetite. These symptoms may appear when you start taking metformin and usually disappear
Frequent: metallic taste, decreased or low vitamin B12 levels in blood (symptoms may include extreme fatigue, pain and redness of the tongue (glossitis), tingling (paresthesia) or pale or yellowish skin). Your doctor may request tests to determine the cause of your symptoms because some of them can also be caused by diabetes or other unrelated health problems.
Very rare: hepatitis (liver problem), hives, skin redness (rash) or itching
Reporting Adverse Effects
If you experience any type of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible adverse effect that does not appear in this prospectus. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es. By reporting adverse effects, you can contribute to providing more information on the safety of this medicine.
Keep this medicine out of sight and reach of children.
Do not use this medicine after the expiration date that appears on the blister pack and on the container after CAD. The expiration date is the last day of the month indicated.
Store below 30 ºC.
Medicines should not be thrown down the drain or into the trash. Deposit the containers and medicines you no longer need at the SIGRE Point of the pharmacy. Ask your pharmacist how to dispose of the containers and medicines you no longer need. This way, you will help protect the environment.
Composition of Sitagliptina/Metformina Almus
o Each film-coated tablet of Sitagliptina/Metformina Almus 50 mg/1.000 mg (tablet) contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin and 1.000 mg of metformin hydrochloride.
o Core of the tablet: povidone (E1201), microcrystalline cellulose PH 102 (E460), crospovidone type A, and sodium stearyl fumarate.
o Film coating: polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), red iron oxide (E172), and black iron oxide (E172).
Appearance of the Product and Content of the Container
Tablet diameter: 21.3 ± 0.5mm
They come in PVC-PVDC and aluminum blisters in containers of 56 and 98 film-coated tablets.
Only some package sizes may be marketed.
Marketing Authorization Holder and Manufacturer
Marketing Authorization Holder
Almus Farmacéutica, S.A.U.
Marie Curie, 54
08840 Viladecans (Barcelona), Spain
Phone: 93 739 71 80
Email: farmacovigilancia@almusfarmaceutica.es
Manufacturer
SAG Manufacturing S.L.U.
Ctra. N-I, Km 36,
28750 San Agustín de Guadalix (Madrid)
Spain
Galenicum Health, S.L.U.
Sant Gabriel 50,
Esplugues de Llobregat
08950 Barcelona
Spain
This medicine is authorized in the member states of the European Economic Area under the following names:
Malta: Sitagliptin/Metformin Diagonalis 50 mg/1.000 mg film-coated tablets
Netherlands: Sitagliptin/Metformin Diagonalis 50 mg /1.000 mg filmomhulde tablet
Poland: Sitagliptin/Metformin Diagonalis 50 mg /1.000 mg powlekana
Date of the last revision of this prospectus: April 2025
Detailed and updated information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/
The average price of SITAGLIPTIN/METFORMIN ALMUS 50 mg / 1000 mg FILM-COATED TABLETS in October, 2025 is around 27.32 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.